138 related articles for article (PubMed ID: 38688610)
21. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
22. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY
Tumori; 2014; 100(2):149-57. PubMed ID: 24852858
[TBL] [Abstract][Full Text] [Related]
23. Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience.
De Felice F; Musio D; Magnante AL; Bulzonetti N; Benevento I; Caiazzo R; Tombolini V
Clin Colorectal Cancer; 2016 Jun; 15(2):e17-22. PubMed ID: 26952656
[TBL] [Abstract][Full Text] [Related]
24. The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade.
Bohlok A; Hendlisz A; Bouazza F; Galdon MG; Van de Stadt J; Moretti L; El Nakadi I; Liberale G
Int J Colorectal Dis; 2018 Oct; 33(10):1383-1391. PubMed ID: 29984385
[TBL] [Abstract][Full Text] [Related]
25. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
Crimì F; Capelli G; Spolverato G; Bao QR; Florio A; Milite Rossi S; Cecchin D; Albertoni L; Campi C; Pucciarelli S; Stramare R
Radiol Med; 2020 Dec; 125(12):1216-1224. PubMed ID: 32410063
[TBL] [Abstract][Full Text] [Related]
26. Rapid Initiation of Neoadjuvant Chemoradiotherapy After Diagnosis is Associated With Improved Pathologic Response in Locally Advanced Rectal Cancer.
Lutsyk M; Turgeman I; Bar-Sela G
Am J Clin Oncol; 2022 Jan; 45(1):1-8. PubMed ID: 34857697
[TBL] [Abstract][Full Text] [Related]
27. Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial.
Velenik V; Zadnik V; Omejc M; Grosek J; Tuta M
Radiol Oncol; 2020 Aug; 54(4):461-469. PubMed ID: 32738130
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
29. The impact of tumor regression grade on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Sakin A; Sahin S; Sengul Samanci N; Yasar N; Demir C; Geredeli C; Erhan SS; Akboru MH; Cihan S
J Oncol Pharm Pract; 2020 Oct; 26(7):1611-1620. PubMed ID: 32046577
[TBL] [Abstract][Full Text] [Related]
30. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
31. Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.
Jacobs L; van der Vlies E; Ten Bokkel Huinink D; Bloemendal H; Intven M; Smits AB; Weusten BLAM; Siersema PD; van Lelyveld N; Los M
Clin Colorectal Cancer; 2018 Sep; 17(3):179-186. PubMed ID: 29661620
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
Ye W; Shi L; Qian L; Sun Y; Sun X
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant-intensified treatment for rectal cancer: time to change?
Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
[TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial.
Golo D; But-Hadzic J; Anderluh F; Brecelj E; Edhemovic I; Jeromen A; Omejc M; Oblak I; Secerov-Ermenc A; Velenik V
Radiol Oncol; 2018 Sep; 52(3):267-274. PubMed ID: 30210040
[TBL] [Abstract][Full Text] [Related]
36. Completion total mesorectal excision after neoadjuvant radiochemotherapy and local excision for rectal cancer.
Coco C; Delrio P; Rega D; Amodio LE; Pucciarelli S; Spolverato G; Belluco C; Lauretta A; Poggioli G; Rocco G; Bianco F; Marsanic P; Sica G; Tondolo V; Rizzo G;
Colorectal Dis; 2024 Feb; 26(2):281-289. PubMed ID: 38131642
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
[TBL] [Abstract][Full Text] [Related]
38. The value of 18F-FDG PET/CT for assessing the response to neoadjuvant therapy in locally advanced rectal cancer.
Murcia Duréndez MJ; Frutos Esteban L; Luján J; Frutos MD; Valero G; Navarro Fernández JL; Mohamed Salem L; Ruiz Merino G; Claver Valderas MA
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):91-7. PubMed ID: 23081822
[TBL] [Abstract][Full Text] [Related]
39. Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer.
Ren DL; Li J; Yu HC; Peng SY; Lin WD; Wang XL; Ghoorun RA; Luo YX
World J Gastroenterol; 2019 Jan; 25(1):118-137. PubMed ID: 30643363
[TBL] [Abstract][Full Text] [Related]
40. Tumor regression grades: can they influence rectal cancer therapy decision tree?
Santos MD; Silva C; Rocha A; Matos E; Nogueira C; Lopes C
Int J Surg Oncol; 2013; 2013():572149. PubMed ID: 24187617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
